Health and Healthcare
Has Alpine Immune Sciences Found the Deal of a Lifetime?
Published:
Alpine Immune Sciences Inc. (NASDAQ: ALPN) shares doubled on Thursday after the company announced a license agreement with AbbVie Inc. (NYSE: ABBV) for its ALPN-101 dual CD28/ICOS costimulation antagonist.
Under the terms of the agreement, Alpine will receive an upfront payment of $60 million and also will be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones.
Note that prior to this move, Alpine Immune Sciences only had a market cap near $90 million.
Additionally, Alpine is eligible to receive tiered royalties on net sales of ALPN-101. In exchange, AbbVie will receive an option to an exclusive license for ALPN-101.
During this option period, Alpine will conduct a phase 2 study in systemic lupus erythematosus. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101.
Note that ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways, which play a big role in multiple autoimmune and inflammatory diseases. Lupus is an example of one of the major diseases that APLN-101 looks to treat.
So far, favorable safety and tolerability, pharmacokinetics and pharmacodynamics have been observed in a first-in-human study in adult healthy volunteers for ALPN-101.
Alpine Immune Sciences stock traded up about 100% early Thursday to $9.74, in a 52-week range of $2.05 to $15.00. The consensus price target is $11.75.
AbbVie stock was relatively flat, at $95.67 in a 52-week range of $62.55 to $99.35. The consensus price target is $100.81.
24/7 Wall St.Take Charge of Your Retirement: Find the Right Financial Advisor For You in Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding professional guidance—and we’ve made it easier than ever for you to connect with the right financial advisor for your unique needs.
Here’s how it works:
1️ Answer a Few Simple Questions
Tell us a bit about your goals and preferences—it only takes a few minutes!
2️ Get Your Top Advisor Matches
This tool matches you with qualified advisors who specialize in helping people like you achieve financial success.
3️ Choose Your Best Fit
Review their profiles, schedule an introductory meeting, and select the advisor who feels right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.